Phase 3 Readout
HEPA: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
October 5, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 5, 2027
- Company
- Hepion Pharmaceuticals, Inc. (HEPA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
- Indication
- Transthyretin Amyloid Cardiomyopathy